CHENGDU, China, Feb. 12, 2025 /PRNewswire/ -- At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2025, to be held in San Francisco, USA, from Feb. 13-15, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd （"Kelun-Biotech" will present efficacy and...
Hence then, the article about study results abstracts from kelun biotech s trop2 adc sacituzumab tirumotecan sac tmt at 2025 asco genitourinary cancers symposium was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) At 2025 ASCO Genitourinary Cancers Symposium )
Also on site :
- Bank of England must plan for a financial crisis triggered by Aliens, says former policy expert
- Finn Wolfhard's 'Stranger Things' SNL Skit Met With Backlash From Fans
- Former UK police officer stripped of citizenship after moving to Russia